1. Bray, F, Ferlay, J, Soerjomataram, I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394–424.
Google Scholar | Crossref | Medline2. Lordick, F, Mariette, C, Haustermans, K, et al. Oesophageal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016; 27: v50–v57.
Google Scholar | Crossref | Medline3. Cunningham, D, Allum, WH, Stenning, SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11–20.
Google Scholar | Crossref | Medline | ISI4. Ychou, M, Boige, V, Pignon, JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 2011; 29: 1715–1721.
Google Scholar | Crossref | Medline | ISI5. Al-Batran, SE, Homann, N, Pauligk, C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet 2019; 393: 1948–1957.
Google Scholar | Crossref | Medline6. van Hagen, P, Hulshof, MCCM, van Lanschot, JJB, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012; 366: 2074–2084.
Google Scholar | Crossref | Medline | ISI7. Ott, K, Weber, WA, Lordick, F, et al. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol 2006; 24: 4692–4698.
Google Scholar | Crossref | Medline8. Lordick, F, Ott, K, Krause, BJ, et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol 2007; 8: 797–805.
Google Scholar | Crossref | Medline | ISI9. Zum Büschenfelde, CM, Herrmann, K, Schuster, T, et al. 18F-FDG PET-guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: the MUNICON II trial. J Nucl Med 2011; 52: 1189–1196.
Google Scholar | Crossref | Medline | ISI10. Goodman, KA, Hall, N, Bekaii-Saab, TS, et al. Survival outcomes from CALGB 80803 (Alliance): a randomized phase II trial of PET scan-directed combined modality therapy for esophageal cancer. J Clin Oncol 2018; 36: 4012–4012.
Google Scholar | Crossref11. Barbour, AP, Walpole, ET, Mai, GT, et al. Preoperative cisplatin, fluorouracil, and docetaxel with or without radiotherapy after poor early response to cisplatin and fluorouracil for resectable oesophageal adenocarcinoma (AGITG DOCTOR): results from a multicentre, randomised controlled phase II trial. Ann Oncol 2020; 31: 236–245.
Google Scholar | Medline12. Harustiak, T, Zemanova, M, Fencl, P, et al. [18 F]Fluorodeoxyglucose PET/CT and prediction of histopathological response to neoadjuvant chemotherapy for adenocarcinoma of the oesophagus and oesophagogastric junction. Br J Surg 2018; 105: 419–428.
Google Scholar | Crossref | Medline13. Goodman, KA, Ou, F-S, Hall, NC, et al. Randomized phase II study of pet response–adapted combined modality therapy for esophageal cancer: mature results of the CALGB 80803 (Alliance) trial. J Clin Oncol 2021; 39: 2803–2815.
Google Scholar | Crossref | Medline14. Boellaard, R, O’Doherty, MJ, Weber, WA, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging 2010; 37: 181–200.
Google Scholar | Crossref | Medline | ISI15. Karstens, KF, Izbicki, JR, Reeh, M. Does the margin matter in esophageal cancer. Dig Surg 2018; 35: 196–203.
Google Scholar | Crossref | Medline16. Mandard, A-M, Dalibard, F, Mandard, J-C, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 1994; 73: 2680–2686.
Google Scholar | Crossref | Medline | ISI17. R Core Team . A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing, 2020, https://www.r-project.org
Google Scholar18. Kelly, RJ, Ajani, JA, Kuzdzal, J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021; 384: 1191–1203.
Google Scholar | Crossref | Medline19. Tepper, J, Krasna, MJ, Niedzwiecki, D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 2008; 26: 1086–1092.
Google Scholar | Crossref | Medline | ISI20. Urba, SG, Orringer, MB, Turrisi, A, et al. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 2001; 19: 305–313.
Google Scholar | Crossref | Medline | ISI21. Leichman, LP, Goldman, BH, Bohanes, PO, et al. S0356: a phase II clinical and prospective molecular trial with oxaliplatin, fluorouracil, and external-beam radiation therapy before surgery for patients with esophageal adenocarcinoma. J Clin Oncol 2011; 29: 4555–4560.
Google Scholar | Crossref | Medline22. Smyth, E, Knödler, M, Giraut, A, et al. VESTIGE: adjuvant immunotherapy in patients with resected esophageal, gastroesophageal junction and gastric cancer following preoperative chemotherapy with high risk for recurrence (N+ and/or R1): an open label randomized controlled phase-2-study. Front Oncol 2020; 9: 1320.
Google Scholar | Crossref | Medline23. Atay-Rosenthal, S, Wahl, RL, Fishman, EK. PET/CT findings in gastric cancer: potential advantages and current limitations. Imaging Med 2012; 4: 241–250.
Google Scholar | Crossref24. Mochiki, E, Kuwano, H, Katoh, H, et al. Evaluation of 18F-2-deoxy-2-fluoro-d-glucose positron emission tomography for gastric cancer. World J Surg 2004; 28: 247–253.
Google Scholar | Crossref | Medline25. De Potter, T, Flamen, P, Van Cutsem, E, et al. Whole-body PET with FDG for the diagnosis of recurrent gastric cancer. Eur J Nucl Med Mol Imaging 2002; 29: 525–529.
Google Scholar | Crossref | Medline26. Stahl, A, Ott, K, Weber, W, et al. FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings. Eur J Nucl Med Mol Imaging 2003; 30: 288–295.
Google Scholar | Crossref | Medline27. Herrmann, K, Ott, K, Buck, AK, et al. Imaging gastric cancer with PET and the radiotracers 18F-FLT and 18F-FDG: a comparative analysis. J Nucl Med 2007; 48: 1945–1950.
Google Scholar | Crossref | Medline28. Ott, K, Herrmann, K, Lordick, F, et al. Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: long-term results of a prospective study. Clin Cancer Res 2008; 14: 2012–2018.
Google Scholar | Crossref | Medline29. Smyth, EC, Verheij, M, Allum, W, et al. Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016; 27: v38–v49.
Google Scholar | Crossref | Medline30. Reynolds, JV, Preston, SR, O’Neill, B, et al. Neo-AEGIS (Neoadjuvant trial in Adenocarcinoma of the Esophagus and Esophago-Gastric Junction International Study): preliminary results of phase III RCT of CROSS versus perioperative chemotherapy (modified MAGIC or FLOT protocol). (NCT01726452). J Clin Oncol 2021; 39: 4004–4004.
Google Scholar | Crossref31. Hoeppner, J, Lordick, F, Brunner, T, et al. ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286). BMC Cancer 2016; 16: 503.
Google Scholar | Crossref | Medline32. Leong, T, Smithers, BM, Haustermans, K, et al. TOPGEAR: a randomized, phase III trial of perioperative ECF chemotherapy with or without preoperative chemoradiation for resectable gastric cancer: interim results from an international, intergroup trial of the AGITG, TROG, EORTC and CCTG. Ann Surg Oncol 2017; 24: 2252–2258.
Google Scholar | Crossref | Medline33. Klevebro, F, Alexandersson von Döbeln, G, Wang, N, et al. A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction. Ann Oncol 2016; 27: 660–667.
Google Scholar | Crossref | Medline34. Kwee, RM, Marcus, C, Sheikhbahaei, S, et al. PET with fluorodeoxyglucose F 18/computed tomography in the clinical management and patient outcomes of esophageal cancer. PET Clin 2015; 10: 197–205.
Google Scholar | Crossref | Medline35. Lorenzen, S, Quante, M, Rauscher, I, et al. PET-directed combined modality therapy for gastroesophageal junction cancer: first results of the prospective MEMORI trial. J Clin Oncol 2019; 37: 4018–4018.
Google Scholar | Crossref